Lawrence Karsh, MD, FACS

Lawrence I Karsh MD FACS is the Director of Research, attending Urologist, and a co-founder of The Urology Center of Colorado. Dr. Karsh has served as the Principal Investigator in over 260 clinical trials. He is an active member of the AUA,SUO,ASCO,ESMO,SBUR,BCAN and ACRP. In addition,he reviews articles for leading Urology journals. He served on the board of the SUO Clinical Trials Consortium from 2010-2020 and is currently co-chairman of the Advanced Therapeutics Clinic at TUCC.
Dr. Karsh did his general surgical training at the University of Colorado Health Sciences Center and completed his urology residency at Brigham and Womens/Harvard Medical School.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:ClovisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:Exact SciencesMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:TolmarMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:ExelexisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:EpizymeMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:SesenMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:MerckMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:KiadisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:TavantaMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Boston ScientificMitigation strategy:DivestDate reviewed:09/20/2022